Plain-English translation of NCT05992597 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment plan using rituximab, lenalidomide, and zebutinib for people who have just been diagnosed with mantle cell lymphoma, a type of cancer that affects the lymph nodes and blood. The study will combine these three medications with additional chemotherapy to see if this approach helps people respond better to treatment. Researchers are measuring how well the treatment works and how safe it is.
Mantle cell lymphoma is an aggressive cancer that is difficult to treat, especially in newly diagnosed patients. This trial is exploring whether this new medication combination might offer better results and help more patients achieve remission (where the cancer goes away or shrinks significantly).
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will first receive three cycles of the three-medication combination (each cycle is 21 days), followed by imaging scans to see how your cancer is responding. Then you'll receive three more cycles of additional chemotherapy. Depending on your response and overall health, you may be offered a stem cell transplant as additional treatment. After that, you'll take zebutinib maintenance medication for 2 years. Throughout the study, you'll have regular clinic visits, blood tests, and imaging scans to monitor your progress and check for side effects.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Zhejiang Cancer Hospital
Enrollment target
~48 participants
Started
August 2022
Primary completion
August 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in September 2023.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.